The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
G-CSF and GM-CSF in Neutropenia
Open accessAbstract
G-CSF and GM-CSF are used widely to promote the production of granulocytes or APCs. The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation. A polyethylene glycol–modified form of G-CSF is approved for the treatment of neutropenias. Clinically significant neutropenia, rendering an individual immunocompromised, occurs when their number is <1500/μl. Current guidelines recommend their use when the risk for febrile neutropenia is >20%. GM-CSF (sargramostim) is approved for neutropenia associated with stem cell transplantation. Because of its promotion of APC function, GM-CSF is being evaluated as an immunostimulatory adjuvant in a number of clinical trials. More than 20 million persons have benefited worldwide, and >$5 billion in sales occur annually in the United States.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472
Manz, M. G., & Boettcher, S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3660 · Cited by 855
Hernandez, P. A., Gorlin, R. J., Lukens, J. N., Taniuchi, S., Bohinjec, J., Francois, F., Klotman, M. E., & Diaz, G. A. (2003) · Nature Genetics · doi:10.1038/ng1149 · Cited by 722 · cited 1×
“Mutations in CXCR4 result in the syndrome (41).”
BackgroundG-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood
Semerad, C. L., Liu, F., Gregory, A. D., Stumpf, K., & Link, D. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00424-7 · Cited by 450
The transcriptional program of terminal granulocytic differentiation
Theilgaard-Mönch, K., Jacobsen, L. C., Borup, R., Rasmussen, T., Bjerregaard, M. D., Nielsen, F. C., Cowland, J. B., & Borregaard, N. (2005) · Blood · doi:10.1182/blood-2004-08-3346 · Cited by 281
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation
Becher, B., Tugues, S., & Greter, M. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.026 · Cited by 593
GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation
Dougan, M., Dranoff, G., & Dougan, S. K. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.022 · Cited by 458
Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J. S. P., Casasnovas, O., Hamad, N., Zijlstra, J. M., Bakhshi, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30120-4 · Cited by 339
Tumor-associated neutrophils and neutrophil-targeted cancer therapies
Que, H., Fu, Q., Lan, T., Tian, X., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188762 · Cited by 312
Metadata
- Authors
- Mehta, H. M., Malandra, M., & Corey, S. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08
- Volume
- 195
- Issue
- 4
- Pages
- 1341-1349
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2135137305
- Cited by
- 363
- References
- 5
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: G-CSF and GM-CSF in Neutropenia. https://app.cochat.ai/papers/10.4049/jimmunol.1500861
- The paper
- Mehta, H. M., Malandra, M., & Corey, S. J. (2015). G-CSF and GM-CSF in Neutropenia. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1500861
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.